Jazz Pharmaceuticals (NASDAQ:JAZZ) Has Target Of $219 Give by Equity Analysts at B. Riley FBR. Buy Didn’t change.

June 27, 2018 - By Kevin Carney

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Corporate Logo

Big Money Sentiment decreased to 1.02 in Q1 2018. It has change of 0.07, from 2017Q4’s 1.09. The ratio dropped due to Jazz Pharmaceuticals plc positioning: 29 sold and 96 reduced. 44 funds bought positions and 84 increased positions. Investors holded 52.98 million in 2017Q4 but now own 51.95 million shares or 1.94% less.

San Francisco Sentry Group (Ca) reported 29 shs. Caisse De Depot Et Placement Du Quebec reported 12,000 shs or 0% of all its holdings. Jane Street Group Incorporated Limited Liability Corporation invested 0% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Sit Investment Associate reported 0.02% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Hbk Limited Partnership accumulated 0.01% or 6,893 shs. 34 were accumulated by Alphamark Advisors Ltd Liability Co. Wellington Mngmt Grp Inc Llp has 0% invested in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) for 68,045 shs. Fifth Third National Bank owns 24 shs. Systematic Management L P, New Jersey-based fund reported 112,402 shs. Nelson Van Denburg Campbell Wealth Mngmt Gru Ltd Limited Liability Company has invested 0.06% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Advisory Net Limited Company stated it has 25 shs. Ameriprise Financial Inc reported 174,360 shs stake. 920 were accumulated by Panagora Asset Management Inc. Tdam Usa reported 2,455 shs. Aperio Gp Limited Liability Company has invested 0.01% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ).

Jazz Pharmaceuticals plc had 23 sales and 0 buys since January 12, 2018. This’s net activity of $5.86 million. MILLER MICHAEL PATRICK had sold 200 shs worth $35,306 on Thursday, June 14. On Friday, May 11 WILSON KAREN J had sold 3,760 shs worth $620,400. 594 shs were sold by Treacy Paul, worth $84,030 on Tuesday, March 6. Shares for $1.18 million were sold by COZADD BRUCE C on Friday, June 1.

Reiterated Jazz Pharmaceuticals (NASDAQ:JAZZ) Rating.

New York: On 26 June, an analyst report was issued to clients and investors of Jazz Pharmaceuticals (NASDAQ:JAZZ). Its Buy Rating reaffirmed by B. Riley FBR. Research professionals have TP of $219 which means 25.22 % upside potential on firm’s stock.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Ratings Coverage

Total analysts of 11 have positions in Jazz Pharmaceuticals (NASDAQ:JAZZ) as follows: 10 rated it a “Buy”, 0 with “Sell” and 1 with “Hold”. The positive are 91%. Since January 2, 2018 according to StockzIntelligence Inc Jazz Pharmaceuticals has 19 analyst reports. On Tuesday, February 20 Bank of America maintained Jazz Pharmaceuticals plc (NASDAQ:JAZZ) rating. Bank of America has “Buy” rating and $170 target. In Thursday, May 10 report FBR Capital maintained it with “Buy” rating and $211 target. On Thursday, April 12 the stock of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has “Buy” rating given by Piper Jaffray. On Friday, March 9 FBR Capital maintained the shares of JAZZ in report with “Buy” rating. On Monday, March 19 Morgan Stanley upgraded the shares of JAZZ in report to “Overweight” rating. On Monday, May 7 the stock of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) earned “Buy” rating by Cantor Fitzgerald. On Monday, June 25 the firm has “Buy” rating given by FBR Capital. In Friday, June 1 report RBC Capital Markets maintained the stock with “Buy” rating. On Tuesday, January 2 the firm has “Buy” rating by Leerink Swann given. On Friday, March 16 the stock of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) earned “Buy” rating by Leerink Swann.

JAZZ is hitting $174.885 during the last trading session, after increased 0.57%.Currently Jazz Pharmaceuticals plc is uptrending after 8.53% change in last June 27, 2017. JAZZ has 127,093 shares volume. JAZZ underperformed by 4.04% the S&P500.

On August, 14 WallStreet anticipated Jazz Pharmaceuticals plc (NASDAQ:JAZZ)’s earnings report, according to Faxor. Analysts have anticipation on stock’s EPS of $2.87. That’s up 66.86 % from last year’s $1.72 EPS. If the current EPS of $2.87 is accurate, JAZZ’s profit could reach $173.02M. Wall Street predicts 9.13 % EPS growth as of August, 14.

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally.The company has $10.54 billion market cap. The firm has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.The P/E ratio is 23.95. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain.

A couple more Jazz Pharmaceuticals plc (NASDAQ:JAZZ) news were brought out by: Streetinsider.com which released on June 27, 2018 “Jazz Pharmaceuticals (JAZZ) PT Raised to $220 at Cowen; ‘Transitioning Growth Asset'”, also Seekingalpha.com on June 01, 2018 brought out “Key events next week – healthcare”, the next Benzinga.com is “Benzinga’s Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street” on June 21, 2018. Prnewswire.com has article titled “Jazz Pharmaceuticals to Present at the Goldman Sachs Global Healthcare Conference”.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: